Semi-daonil en es it fr

Semi-daonil Brand names, Semi-daonil Analogs

Semi-daonil Brand Names Mixture

  • No information avaliable

Semi-daonil Chemical_Formula


Semi-daonil RX_link

Semi-daonil fda sheet

Semi-daonil msds (material safety sheet)

Semi-daonil MSDS

Semi-daonil Synthesis Reference

Weber et al., U.S. Pat. 3,454,635 (1969)

Semi-daonil Molecular Weight

494.004 g/mol

Semi-daonil Melting Point


Semi-daonil H2O Solubility

4 mg/L

Semi-daonil State


Semi-daonil LogP


Semi-daonil Dosage Forms

Tablet (1.25 mg, 2.5 mg, 5 mg)

Semi-daonil Indication

Indicated as an adjunct to diet to lower the blood glucose in patients with non-insulin-dependent diabetes mellitus (Type II) whose hyperglycemia cannot be satisfactorily controlled by diet alone.

Semi-daonil Pharmacology

Glyburide, a second-generation sulfonylurea antidiabetic agent, appears to lower the blood glucose acutely by stimulating the release of insulin from the pancreas, an effect dependent upon functioning beta cells in the pancreatic islets. With chronic administration in Type II diabetic patients, the blood glucose lowering effect persists despite a gradual decline in the insulin secretory response to the drug. Extrapancreatic effects may be involved in the mechanism of action of oral sulfonyl-urea hypoglycemic drugs. The combination of glyburide and metformin may have a synergistic effect, since both agents act to improve glucose tolerance by different but complementary mechanisms. In addition to its blood glucose lowering actions, glyburide produces a mild diuresis by enhancement of renal free water clearance. Glyburide is twice as potent as the related second-generation agent glipizide.

Semi-daonil Absorption

Significant absorption within 1 hour and peak plasma levels are reached within 4 hours.

Semi-daonil side effects and Toxicity

Oral rat LD50: > 20,000 mg/kg. Oral mouse LD50: 3250 mg/kg.

Semi-daonil Patient Information

Patients should be informed of the potential risks and advantages of MICRONASE and of alternative modes of therapy. They also should be informed about the importance of adherence to dietary instructions, of a regular exercise program, and of regular testing of urine and/or blood glucose.

The risks of hypoglycemia, its symptoms and treatment, and conditions that predispose to its development should be explained to patients and responsible family members. Primary and secondary failure also should be explained.

Semi-daonil Organisms Affected

Humans and other mammals